Shots:Servier has entered into a definitive agreement with Kaerus Bioscience to acquire KER-0193, a potential treatment for Fragile X syndrome (FXS)As per the deal, Kaerus will receive a total of ~$450M incl. an upfront payment as well as development & commercial milestonesKER-0193 is a BK channel modulator, which showed improvement across syndrome-relevant…
